Reversible Mitochondrial Protein Acetylation and Metabolic Regulation

可逆线粒体蛋白乙酰化和代谢调节

• 批准号: 9100715
• 负责人: Eric M. Verdin
• 金额: $ 155.06万
• 依托单位: J. DAVID GLADSTONE INSTITUTES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9100715
• 关键词: Acetylation; Acylation; Affect; Aging-Related Process; Animal Model; Beta Cell; Biological; Biological Assay; Branched-Chain Amino Acids; Carbohydrates; Catabolism; Cells; Chronic; Citric Acid Cycle; Clinical; Cytoplasm; Data; Development; Diabetes Mellitus; Diet; Disease; Enzymes; Fasting; Fatty acid glycerol esters; Fructose; Genetic; Genetic Polymorphism; Glucose; Goals; Grant; Health; Hepatocyte; High Fat Diet; Homeostasis; Human; Inflammation; Insulin; Islets of Langerhans; Ketone Bodies; Knock-out; Knockout Mice; Link; Lipids; Liver; Liver Mitochondria; Lysine; Mass Spectrum Analysis; Measurement; Metabolic; Metabolic Diseases; Metabolic Pathway; Metabolic stress; Metabolic syndrome; Metabolism; Mitochondria; Mitochondrial Proteins; Modeling; Modification; Molecular Biology; Monoclonal Antibody R24; Mus; Muscle; Muscle Cells; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Oxidative Stress; Pancreas; Paper; Pathogenesis; Pathologic; Pathway interactions; Physiological; Play; Post-Translational Protein Processing; Process; Protein Acetylation; Proteins; Proteomics; Publications; Publishing; Regulation; Resolution; Respiratory Chain; Risk; Role; Sirtuins; Site-Directed Mutagenesis; Skeletal Muscle; Steatohepatitis; Structure of beta Cell of islet; Syndrome; Testing; Tissue Engineering; Tissues; Transgenic Organisms; Variant; Work; base; enzyme pathway; fatty acid oxidation; feeding; flexibility; in vivo; insulin sensitivity; insulin signaling; ketogenesis; metabolomics; mitochondrial dysfunction; mitochondrial metabolism; mouse model; multidisciplinary; multiple reaction monitoring; novel; novel strategies; novel therapeutics; overexpression; pyruvate dehydrogenase; response; tool; urea cycle

 DESCRIPTION (provided by applicant): This is a competitive renewal of an R24 grant focused on mitochondrial protein acylation, its regulation by the NAD-dependent mitochondrial protein deacylases, SIRT3 and SIRT5, and their impact on metabolic regulation under normal and pathological conditions. During the first 48 months of this grant, our collaborative group has published 27 papers and has defined the function of SIRT3 and SIRT5 as key mitochondrial NAD-dependent protein deacylases. In the mitochondria, SIRT3 and SIRT5 regulates the acetylation (SIRT3) and succinylation (SIRT5) of many mitochondrial enzymes in key metabolic pathways that include fatty acid oxidation, ketone body synthesis, TCA cycle, OXPHOS and the urea cycle. Loss of SIRT3 is associated with reduced metabolic flexibility and accelerated development of a syndrome that mimics human metabolic syndrome with obesity, type 2 diabetes, lipid abnormalities, and steatohepatitis. Mice lacking SIRT5 also showed significant metabolic abnormalities in the urea cycle, ketogenesis and fatty acid oxidation. SIRT5 is also an NAD-dependent demalonylase but this modification targets distinct proteins predominantly in the cytoplasm. These findings point to reversible mitochondrial protein acylation as a key regulator of mitochondrial metabolism and SIRT3 and SIRT5 as important factors in the pathogenesis of type 2 diabetes and the metabolic syndrome. The overall goal of this proposal is to extend these studies to further define the role of protein acylation and SIRT3 and SIRT5 in mitochondrial function in unique tissues involved in the pathogenesis of the metabolic syndrome: liver, muscle and pancreatic ß cells. We will take advantage of our highly collaborative and multidisciplinary team harnessing the power of mass spectrometry-based proteomics, metabolomics, molecular biology, extensive physiological testing and unique and novel animal models, including tissue-specific knockouts and tissue specific transgenic overexpressors for SIRT3 and SIRT5, to further increase our understanding of this important process in regulation of mitochondrial function and metabolism.

 描述（由申请人提供）：这是R24资助的竞争性更新，重点是线粒体蛋白酰化，其通过NAD依赖性线粒体蛋白脱酰酶SIRT3和SIRT5的调节，以及它们对正常和病理条件下代谢调节的影响。在该资助的前48个月，我们的合作小组发表了27篇论文，并将SIRT3和SIRT5的功能定义为关键的线粒体NAD依赖性蛋白脱酰酶。在线粒体中，SIRT3和SIRT5调节关键代谢途径中许多线粒体酶的乙酰化（SIRT3）和琥珀酰化（SIRT5），所述代谢途径包括脂肪酸氧化、酮体合成、TCA循环、OXPHOS和尿素循环。SIRT3的缺失与代谢灵活性降低和一种综合征的加速发展有关，该综合征模拟具有肥胖、2型糖尿病、脂质异常和脂肪性肝炎的人类代谢综合征。缺乏SIRT5的小鼠在尿素循环、生酮和脂肪酸氧化方面也表现出显著的代谢异常。SIRT5也是NAD依赖性脱丙二酸酶，但这种修饰主要靶向细胞质中的不同蛋白质。这些发现表明可逆的线粒体蛋白酰化是线粒体代谢的关键调节因子，SIRT3和SIRT5是2型糖尿病和代谢综合征发病机制中的重要因素。该提案的总体目标是扩展这些研究，以进一步确定蛋白酰化和SIRT3和SIRT5在参与代谢综合征发病机制的独特组织（肝脏，肌肉和胰腺癌细胞）中线粒体功能中的作用。我们将利用我们高度协作和多学科的团队，利用基于质谱的蛋白质组学，代谢组学，分子生物学，广泛的生理学测试和独特和新颖的动物模型的力量，包括SIRT3和SIRT5的组织特异性敲除和组织特异性转基因过表达，以进一步增加我们对线粒体功能和代谢调节中这一重要过程的理解。